AEB071 – a promising immunosuppressive agent
- 11 November 2009
- journal article
- review article
- Published by Wiley in Clinical Transplantation
- Vol. 23 (s21) , 15-18
Abstract
In the past decades, allograft survival improved because of the development of new and more specific immunosuppressive agents. The introduction of calcineurin inhibitors was a landmark and acute rejection in organ transplantation decreased remarkably. Calcineurin inhibitor such as ciclosporin A inhibits T-cell activation by interfering with the cytosolic protein cyclophilin (immunophilin). This complex of ciclosporin and cyclophilin inhibits calcineurin, which is responsible for activating the transcription of interleukin-2. More recent research revealed a second pathway for T-cell activation, which is mediated by a specific protein kinase C., e.g., protein kinase C theta. AEB071 represents a selective protein kinase C inhibitor with promising potential for immunosuppression in organ transplantation. In pre-clinical studies, AEB071 prolonged allograft survival in kidney and heart transplant models. In human clinical studies, AEB071 reduced severity of psoriasis symptoms and has shown to be safe up to 750 mg single dose treatment. Important adverse events were gastrointestinal disorders and headaches. AEB071 inhibits early T-cell activation via a calcineurin inhibitor independent pathway and is currently investigated as a therapeutic agent to prevent allograft rejection after renal transplantation.Keywords
This publication has 14 references indexed in Scilit:
- The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell ActivationThe Journal of Pharmacology and Experimental Therapeutics, 2009
- The PKC inhibitor AEB071 may be a therapeutic option for psoriasisJournal of Clinical Investigation, 2008
- Targeting the protein kinase C family: are we there yet?Nature Reviews Cancer, 2007
- Mycophenolate Mofetil and Sirolimus Combination in Renal TransplantationAmerican Journal of Transplantation, 2006
- Slowing the Progression of Chronic Allograft Nephropathy by Conversion from Cyclosporine to Tacrolimus: A Randomized Controlled TrialTransplantation, 2006
- Protein kinase C and beyondNature Immunology, 2004
- Cyclosporin A Toxicity of the Renal Allograft – a Late Complication and Potentially ReversibleNephron, 2002
- Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996New England Journal of Medicine, 2000
- Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric TransplantNew England Journal of Medicine, 1999
- Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimensThe Lancet, 1998